Affected by the shift in Federal Reserve policy, geopolitical sentiments, and other factors, the Hong Kong stock market has recently faced significant pressure, with major indices continuing to fluctuate downward. On March 23, the Hang Seng Index fell below the 25,000-point mark during trading, while the Hang Seng Tech Index also dropped below 4,800 points, with both core indices hitting new lows for the year.
As the Hong Kong stock market undergoes an overall correction, the valuation pressure on key sectors such as technology, pharmaceuticals, and consumer goods has been somewhat alleviated, and the allocation value may gradually become apparent. The market attention on index products such as the Hang Seng Tech ETF Huatai-PB (513130), Hang Seng Biotechnology ETF Huatai-PB (513930), Hang Seng Consumer ETF Huatai-PB (520520), and Hang Seng Innovative Drug ETF Huatai-PB (520500) continues to rise.
According to Wind data, all domestic ETFs tracking the Hang Seng Company Index experienced a cumulative net outflow of funds for three consecutive trading days from March 13 to March 17, 2026. However, from March 18 to March 20, they successfully reversed the fund flow, achieving net inflows for three consecutive trading days, with a cumulative net inflow amounting to 2.316 billion yuan. This indicates that some funds have begun to gradually allocate to quality core assets in the Hong Kong stock market through ETFs, possibly reflecting a positive attitude towards the subsequent market recovery.
In terms of investment tools for the Hong Kong stock market, Huatai-PB has a well-established layout, with multiple quality Hang Seng series ETFs, including the Hang Seng Tech ETF Huatai-PB (513130), Hang Seng Biotechnology ETF Huatai-PB (513930), Hang Seng Consumer ETF Huatai-PB (520520), and Hang Seng Innovative Drug ETF Huatai-PB (520500), covering core sectors of the Hong Kong stock market and providing investors with convenient and efficient allocation channels.
Among them, the Hang Seng Tech ETF Huatai-PB (513130), which includes leading technology stocks in the Hong Kong market, has seen its shares grow for four consecutive trading days, surpassing 80 billion shares; the Hang Seng Consumer ETF Huatai-PB (520520) has also attracted funds, with a 78.57% increase in shares over the past two trading days; in the Hong Kong pharmaceutical sector, the Hang Seng Innovative Drug ETF Huatai-PB (520500) focuses precisely on the core innovative drug sector, while the Hang Seng Biotechnology ETF Huatai-PB (513930) balances both the CXO and innovative drug core fields, meeting the diverse needs of different investors.
As one of the first ETF managers in the market, Huatai-PB has been deeply involved in the index investment field for nearly 20 years, creating the market's first dividend-themed ETF and the first cross-market ETF, the CSI 300 ETF Huatai-PB, among other products. By the end of 2025, the company's ETFs have cumulatively generated over 164 billion yuan in profits for holders over the past two years, making it one of only four fund companies in the market to achieve cumulative profits exceeding 100 billion yuan during the same period; in terms of fees, 77.8% of the company's ETF products adopt the lowest fee structure currently available in the market for equity index funds (management fee rate of 0.15% per year + custody fee rate of 0.05% per year)
Daily Economic News

03032

159742

00HSI

The Hong Kong stock market has recently come under pressure, with major indices continuing to decline, and the Hang Seng Index and Hang Seng TECH Index hitting new lows for the year. As the market adjusts, valuation pressures in sectors such as technology, pharmaceuticals, and consumer goods are being released, and the allocation value is gradually becoming apparent. The Hang Seng series ETFs from Huatai-PB have attracted attention, with significant signs of capital inflow, especially in the Hang Seng TECH ETF and Hang Seng Consumer ETF, which have seen notable increases in shares, indicating a positive attitude from investors towards core assets in the Hong Kong stock market

腾讯新闻 - 财经

HSTECH ETF

Hang Seng TECH ETF I

Hang Seng Index

Tianhong Hang Seng TECH ETF(QDII)

Huatai-PB CSOP Hang Seng Technology ETF(QDII)

Hang Seng TECH Index

CSOP HS TECH

TRACKER FUND

ISHARESHSI

China Southern Hang Seng TECH ETF(QDII)

Dacheng Hang Seng Technology ETF(QDII)

ISHARESHSTECH

China Southern Hang Seng ETF

CAM HS TECH

ChinaAMC Hang Seng Technology ETF(QDII)

The continuous pullback of Hong Kong stocks attracts capital inflow, and the Huatai-PB Hang Seng series ETFs assist in seizing recovery opportunities